Related Experiment Videos
First rotavirus vaccine licensed: is there really a need?
R I Glass1, J S Bresee, U D Parashar
1Viral gastroenteritis Section, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Acta Paediatrica (Oslo, Norway : 1992). Supplement
|March 24, 1999
Summary
The first rotavirus vaccine prevents severe diarrhea in children. European health officials should reconsider its routine use due to the vaccine's proven efficacy and cost-effectiveness.
Area of Science:
- Pediatrics
- Vaccinology
- Public Health
Background:
- Rotavirus is a leading cause of severe diarrhea and hospitalizations in children globally.
- Despite its prevalence, European healthcare professionals question the necessity of rotavirus vaccination for infants.
- Disease burden and cost-effectiveness studies for rotavirus immunization are limited in Europe.
Purpose of the Study:
- To evaluate the need for rotavirus vaccine in routine infant immunization in Europe.
- To highlight the disease burden of rotavirus diarrhea in children.
- To discuss the cost-effectiveness of rotavirus immunization programs.
Main Methods:
- Review of existing epidemiological data on rotavirus disease burden in Europe and the United States.
- Analysis of the efficacy, safety, and cost-effectiveness of the first rotavirus vaccine.
- Comparison of disease incidence and hospitalization rates across different regions.
Main Results:
- Rotavirus causes 30-50% of diarrheal hospitalizations in children under 5.
- 1 in 40 to 1 in 77 children in Europe and the US may be hospitalized for rotavirus by age 5.
- The first rotavirus vaccine demonstrates good efficacy, low adverse effects, and positive cost-effectiveness.
Conclusions:
- An effective rotavirus vaccine is now available for preventing severe diarrhea in infants.
- European physicians and policymakers should reassess rotavirus epidemiology and disease burden.
- Routine rotavirus vaccination is recommended in the U.S. due to its benefits.